After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer

BJU International

Volumn 101, Issue 2, 2008, Pages 170-174

  Sengupta, Shomik ^a   Blute, Michael L ^a   Bagniewski, Stephanie M ^a   Inman, Brant ^a   Leibovich, Bradley C ^a   Slezak, Jeffrey M ^a   Myers, Robert P ^a   Zincke, Horst ^a  

^a MAYO CLINIC   (United States)

Author keywords

Histopathology; Prognosis; Prostate cancer; Radical retropubic prostatectomy; Survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; DISEASE FREE SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; RISK ASSESSMENT; RISK FACTOR; SEMINAL VESICLE; TREATMENT OUTCOME; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; COHORT STUDIES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 37349054311     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07270.x     Document Type: Article

References (28)

1. Cagiannos I, Karakiewicz P, Graefen M et al. Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol 2004 171 : 692 6
2. Taylor JA 3rd, Gancarczyk KJ, Fant GV, McLeod DG. Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer. Urology 2002 60 : 841 5
3. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993 71 : 933 8
4. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994 271 : 368 74
5. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996 275 : 288 94
6. Anast JW, Andriole GL, Bismar TA, Yan Y, Humphrey PA. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 2004 64 : 544 50
7. Kattan MW, Eastham JA, Wheeler TM et al. Counseling men with prostate cancer. a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003 170 : 1792 7
8. Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004 101 : 2001 5
9. Augustin H, Hammerer PG, Graefen M et al. Insignificant prostate cancer in radical prostatectomy specimen. time trends and preoperative prediction. Eur Urol 2003 43 : 455 60
10. Cheng L, Poulos CK, Pan CX et al. Preoperative prediction of small Volume cancer (less than 0.5 ml) in radical prostatectomy specimens. J Urol 2005 174 : 898 902
11. Miyake H, Sakai I, Harada K, Hara I, Eto H. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease. Int J Urol 2005 12 : 270 4
12. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001 76 : 576 81
13. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001 165 : 1146 51
14. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001 165 : 119 25
15. Klein EA. What is 'insignificant' prostate carcinoma? Cancer 2004 101 : 1923 5
16. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005 352 : 1977 84
17. Allsbrook WC Jr., Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI. Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol 2001 32 : 81 8
18. Mills SE, Fowler JE Jr. Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens. Cancer 1986 57 : 346 9
19. Obek C, Louis P, Civantos F, Soloway MS. Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. J Urol 1999 161 : 494 8
20. Smith JA Jr., Scardino PT, Resnick MI, Hernandez AD, Rose SC, Egger MJ. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol 1997 157 : 902 6
21. Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The Volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995 153 : 1543 8
22. Boccon-Gibod LM, de Longchamps NB, Toublanc M, Boccon-Gibod LA, Ravery V. Prostate saturation biopsy in the reevaluation of microfocal prostate cancer. J Urol 2006 176 : 961 3
23. Epstein JI, Sanderson H, Carter HB, Scharfstein DO. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 2005 66 : 356 60
24. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999 53 : 581 9
25. Sindhwani P, Wilson CM. Prostatitis and serum prostate-specific antigen. Curr Urol Rep 2005 6 : 307 12
26. Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005 174 : 2191 6
27. Kramer NM, Hanlon AL, Horwitz EM, Pinover WH, Hanks GH. Biochemical failure rates in prostate cancer patients predicted to have biologically insignificant tumors treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2002 53 : 277 81
28. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005 23 : 8165 9